# Persistence Of Antibody Responses Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine or Meningococcal C Conjugate Vaccine

> **NCT01345721** · PHASE3 · COMPLETED · sponsor: **Novartis Vaccines** · enrollment: 205 (actual)

## Conditions studied

- Meningococcal Disease

## Interventions

- **BIOLOGICAL:** MenACWY-CRM

## Key facts

- **NCT ID:** NCT01345721
- **Lead sponsor:** Novartis Vaccines
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05
- **Primary completion:** 2011-09
- **Final completion:** 2011-09
- **Target enrollment:** 205 (ACTUAL)
- **Last updated:** 2018-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01345721

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01345721, "Persistence Of Antibody Responses Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine or Meningococcal C Conjugate Vaccine". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01345721. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*